Welcome to our dedicated page for Zai Lab news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab stock.
Zai Lab Limited (ZLAB) is a research-based, commercial-stage biopharmaceutical company based in China and the United States, with a focus on oncology, immunology, neuroscience, and infectious disease. The Zai Lab news feed on Stock Titan aggregates company announcements, clinical updates, regulatory milestones, and financial disclosures that the company releases through channels such as Business Wire and SEC filings.
Investors and followers of ZLAB stock can use this page to review news on Zai Lab’s global pipeline, including progress of assets like zocilurtatug pelitecan (zoci), a DLL3-targeted antibody-drug conjugate for extensive-stage small cell lung cancer and other neuroendocrine carcinomas, and ZL-1503, an IL-13/IL-31R bispecific antibody for atopic dermatitis. Updates on other oncology and immunology programs, such as ZL-6201, ZL-1222, and ZL-1311, also appear in company press releases.
The news stream highlights regulatory developments in Greater China, including National Medical Products Administration (NMPA) approvals and National Reimbursement Drug List (NRDL) decisions for products in Zai Lab’s commercial portfolio. Recent examples include announcements about COBENFY for schizophrenia and AUGTYRO for ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors, as well as renewals and coverage decisions for VYVGART, NUZYRA, and ZEJULA.
In addition, this page surfaces Zai Lab’s financial result releases, conference call notices, and participation in healthcare and investor conferences. These items provide context on revenue trends, R&D spending, and the company’s dual-engine strategy combining a China commercial business with a global innovation platform. Bookmark this page to quickly access ZLAB-related news, organized in one place for efficient review of the company’s ongoing clinical, regulatory, and corporate developments.
Zai Lab (NASDAQ: ZLAB) announced positive topline results from its Phase 3 trial of KarXT for schizophrenia treatment in China. The trial met its primary endpoint, showing a significant 9.2-point reduction in PANSS Total score versus placebo at Week 5. The study also achieved all secondary endpoints, demonstrating improvements in positive and negative symptoms. Key results include a 1.9-point reduction in PANSS positive subscale and 2.5-point reduction in negative subscale versus placebo. The safety profile was consistent with previous trials. Based on these results, Zai Lab plans to submit a New Drug Application to China's NMPA in early 2025.
Zai Lab presented promising Phase 1a/1b study results for ZL-1310, a next-generation antibody-drug conjugate (ADC), in treating extensive-stage Small Cell Lung Cancer. The study showed a 74% objective response rate across all dose levels in previously treated patients. Key findings include positive responses in patients with brain metastases and favorable safety profile with mainly Grade 1 or 2 adverse events. Of 25 patients treated, only 20% experienced Grade ≥3 treatment-related adverse events, with neutropenia being most common. The drug demonstrated efficacy across various DLL3 expression levels, with 13 of 14 responders still on treatment.
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has announced its participation in three upcoming investor conferences. The company's senior management team will attend the Goldman Sachs APAC Healthcare Corporate Day 2024 in Hong Kong from November 5-8, 2024. They will also participate in the Jefferies London Healthcare Conference, featuring a fireside chat on Tuesday, November 19, 2024, at 1:30 p.m. GT in Aldwych, London. Lastly, Zai Lab will be present at Citi's 2024 Global Healthcare Conference in Miami, Florida, from December 3-5, 2024.
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has announced an upcoming investor webcast to discuss data from a Phase 1 clinical trial of ZL-1310, their investigational DLL3-targeted antibody-drug conjugate (ADC) for patients with advanced stage small cell lung cancer (SCLC). The live conference call and webcast is scheduled for October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT), following a plenary oral presentation at the EORTC-NCI-AACR Symposium (ENA) 2024.
Interested parties can access the live webcast through Zai Lab's website at http://ir.zailaboratory.com. Participants must register in advance using the provided link: https://register.vevent.com/register/BI6f8ba8dc42d04cd3afd7095cf7c83d40. Upon registration, dial-in details will be sent via confirmation email. A replay of the webcast will be available on the company's website shortly after the call.
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has announced that it will release its third quarter 2024 financial results and provide recent corporate updates before the U.S. equity markets open on Tuesday, November 12, 2024. The company will host a live conference call and webcast on the same day at 8:00 a.m. ET (9:00 p.m. HKT).
Interested parties can access the live webcast through Zai Lab's website at http://ir.zailaboratory.com. To participate in the conference call, attendees must register in advance using the provided link. Upon registration, participants will receive dial-in details via email. A replay of the call will be available on the company's website shortly after the event concludes.
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) announced that data from a Phase 1 study of ZL-1310, its investigational antibody-drug conjugate (ADC), will be presented at the EORTC-NCI-AACR Symposium (ENA) 2024 in Barcelona. The presentation will focus on ZL-1310's potential as a novel treatment for small cell lung cancer (SCLC). ZL-1310 targets Delta-like ligand 3 (DLL3), which is overexpressed in many neuroendocrine tumors and associated with poor clinical outcomes.
The compound features a novel linker-payload platform called TMALIN®, designed to overcome challenges of first-generation ADC therapies. Dr. Rafael G. Amado, President and Head of Global R&D at Zai Lab, emphasized the need for new therapies with reduced off-target toxicity and increased anti-tumor effectiveness for SCLC and other neuroendocrine tumors. The presentation, titled 'Preliminary Results from a Phase 1a/1b, Open-Label, Multicenter Study of ZL-1310,' will be given by Dr. Alex Spira on October 24, 2024.
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) will present preclinical data on ZL-1503, an IL-13/IL-31 bispecific antibody for treating atopic dermatitis, at the EADV Congress 2024. This internally developed drug targets both inflammatory and pruritogenic pathways, potentially offering improved treatment for moderate-to-severe atopic dermatitis and related conditions. Current IL-4/IL-13 inhibitors have limitations in addressing IL-31-mediated symptoms, resulting in slow and modest clinical responses. ZL-1503 aims to inhibit both IL-13 and IL-31 signaling pathways, potentially expanding treatment options. The late-breaking oral presentation, scheduled for September 25, 2024, will discuss ZL-1503's potential as a novel treatment for atopic dermatitis and other IL-13/IL-31 related diseases.
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) will present preliminary data from a Phase 1 trial of ZL-1218, an investigational anti-CCR8 antibody for advanced solid tumors, at the ESMO Congress 2024. The study (NCT05859464) aims to demonstrate ZL-1218's potential to reduce regulatory T cells and modulate T-cell function in the tumor microenvironment. ZL-1218 is a humanized monoclonal antibody targeting CCR8, a receptor on tumor-associated regulatory T cells, potentially enhancing antitumor immune response.
The ongoing global Phase 1 study evaluates ZL-1218 as a single agent and in combination with pembrolizumab. Dr. Rafael G. Amado, President and Head of Global R&D at Zai Lab, highlighted the importance of overcoming tumor microenvironment complexities in cancer immunotherapy. The poster presentation at ESMO 2024 will focus on preliminary clinical PK and PD analysis of ZL-1218 in patients with advanced solid tumors.
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has announced its participation in two major investor conferences in September 2024. The company's senior management team will attend the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Additionally, they will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 19, 2024, at 8:00 a.m. ET in Track 2, also held in New York.
These conferences provide Zai Lab with opportunities to engage with investors and showcase their company's progress and future plans in the healthcare sector.
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) reported strong Q2 2024 financial results, with net product revenue of $100.1 million, up 45% year-over-year. VYVGART sales reached $23.2 million, prompting a raised full-year guidance to exceed $80 million. The company expanded its oncology pipeline with a new ROR1 ADC program. Three product approvals were obtained in China, including XACDURO for HABP/VABP, efgartigimod SC for gMG, and AUGTYRO for ROS1+ NSCLC. Zai Lab maintains a strong cash position of $730 million as of June 30, 2024. The company expects at least four regulatory submissions to the NMPA within the next 12 months, including KarXT for schizophrenia.